Application of CD54 in diagnosing bone marrow involvement by using flow cytometry in patients with diffuse large B-cell lymphoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Flow Cytometry*; Biomarkers, Tumor/*analysis ; Bone Marrow/*chemistry ; Intercellular Adhesion Molecule-1/*analysis ; Lymphoma, Large B-Cell, Diffuse/*chemistry; Adult ; Aged ; Aged, 80 and over ; B-Lymphocytes/chemistry ; B-Lymphocytes/metabolism ; Biomarkers, Tumor/metabolism ; Biopsy ; Bone Marrow/metabolism ; Bone Marrow/pathology ; Cell Adhesion Molecules/analysis ; Cell Adhesion Molecules/metabolism ; Cell Differentiation ; Female ; Germinal Center/chemistry ; Germinal Center/metabolism ; Germinal Center/pathology ; Humans ; Immunophenotyping ; Intercellular Adhesion Molecule-1/metabolism ; Lymphoma, Large B-Cell, Diffuse/metabolism ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Middle Aged ; Plasma Cells/cytology
    • Abstract:
      Background: Flow cytometry plays a key role in detecting bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL). To improve its detection sensitivity, we need to explore novel markers. In this study, we detected the expression CD54 on lymphoma cells in BM specimens from DLBCL patients and clarified its diagnostic significance in BM involvement by DLBCL.
      Methods: We collected BM specimens from 76 patients with DLBCL (germinal center B-cell (GCB) = 25, non-GCB = 51) and 10 control patients without lymphoma. We detected and compared the expression of CD54 on lymphoma cells and normal mature B cells by using 10-color panels.
      Results: Normal plasma cells expressed a higher level of CD54 as compared with hematogones (p < 0.05) and normal mature B cells (p < 0.05). Among 76 patients, 23 of them (GCB = 12, non-GCB = 11) had BM involvement. Lymphoma B cells from 12 cases (GBC = 4, non-GCB = 8) expressed a higher level of CD54 compared to normal mature B cells (p < 0.05). Additionally, lymphoma cells of the non-GCB subtype frequently expressed a higher level of CD54 in comparison to the GCB subtype (p < 0.05). And the high expression of CD54 was not related to plasmacytoid differentiation.
      Conclusion: Aberrant expression of CD54 on lymphoma cells is frequently seen in patients' BM specimens involved by DLBCL, especially in the non-GCB subtype. CD54 could be used as a new marker to gate on lymphoma cells and improve the detection sensitivity of BM involvement in patients with DLBCL.
      (© 2021. The Author(s).)
    • References:
      Ann Oncol. 2003 Feb;14(2):273-6. (PMID: 12562655)
      Leuk Lymphoma. 2019 Oct;60(10):2477-2482. (PMID: 31014136)
      J Immunol. 1991 Mar 15;146(6):1773-82. (PMID: 1672331)
      Blood. 2016 Feb 25;127(8):965-70. (PMID: 26679865)
      Proc Natl Acad Sci U S A. 1988 May;85(9):3095-9. (PMID: 3362863)
      Eur J Haematol. 2006 Jun;76(6):473-80. (PMID: 16529599)
      J Clin Oncol. 1998 Jan;16(1):35-40. (PMID: 9440720)
      Acta Haematol. 2009;121(4):196-201. (PMID: 19468204)
      Blood. 2016 May 19;127(20):2375-90. (PMID: 26980727)
      Leuk Lymphoma. 2015;56(12):3301-5. (PMID: 25813204)
      Am J Clin Pathol. 2010 May;133(5):718-26. (PMID: 20395518)
      Cytometry B Clin Cytom. 2019 Jan;96(1):20-29. (PMID: 30549186)
      Leuk Res. 2013 Nov;37(11):1404-11. (PMID: 23932356)
      Am J Clin Pathol. 2002 Apr;117(4):644-50. (PMID: 11939741)
      Am J Clin Pathol. 1994 Mar;101(3):305-11. (PMID: 8135186)
      Cancer. 2000 Feb 15;88(4):894-9. (PMID: 10679660)
      Am J Clin Pathol. 2004 Apr;121(4):464-72. (PMID: 15080297)
      Cytometry B Clin Cytom. 2018 May;94(3):451-458. (PMID: 28509416)
      Blood. 2007 Aug 15;110(4):1278-82. (PMID: 17475910)
      Int J Lab Hematol. 2010 Dec;32(6 Pt 1):e190-6. (PMID: 20201998)
      Turk J Haematol. 2017 Mar 1;34(1):81-88. (PMID: 27956371)
      Mayo Clin Proc. 2008 Jul;83(7):776-85. (PMID: 18613994)
      Leukemia. 2010 Mar;24(3):512-20. (PMID: 20090778)
      Hum Pathol. 2010 Feb;41(2):271-80. (PMID: 20004001)
      J Clin Pathol. 2013 May;66(5):420-5. (PMID: 23610041)
      Am J Clin Pathol. 2004 Apr;121(4):482-8. (PMID: 15080299)
      J Immunol. 2011 Oct 15;187(8):3931-41. (PMID: 21918187)
      Haematologica. 2013 Oct;98(10):1571-80. (PMID: 23831923)
      Ann Lab Med. 2015 Mar;35(2):187-93. (PMID: 25729719)
      Histopathology. 2004 Sep;45(3):268-74. (PMID: 15330805)
      Clin Cancer Res. 2000 Oct;6(10):3904-9. (PMID: 11051236)
      J Exp Med. 1988 Jun 1;167(6):1811-24. (PMID: 2898508)
      J Mol Med (Berl). 1996 Jan;74(1):13-33. (PMID: 8834767)
    • Contributed Indexing:
      Keywords: Bone marrow involvement; CD54; Diffuse large B-cell lymphoma; Flow cytometry
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (Cell Adhesion Molecules)
      126547-89-5 (Intercellular Adhesion Molecule-1)
    • Publication Date:
      Date Created: 20210910 Date Completed: 20211014 Latest Revision: 20211014
    • Publication Date:
      20240105
    • Accession Number:
      PMC8431857
    • Accession Number:
      10.1186/s12885-021-08753-0
    • Accession Number:
      34503477